Clinical Trial Search

Primary: Effectiveness of Oral Tofacitinib in Recalcitrant Frontal Fibrosing Alopecia(FFA) — 47.5; 44; 16.3; 15.9 score on a scale

Primary: Change in Patient-Reported Itch — -0.33 units on a scale

Primary: Total Number of Participants With At Least 50% Hair Regrowth — 1 Participants

Primary: Number of Patients With SALT50 — 1; 1 Participants

Primary: Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24 — -6.3; 2.3 score on a scale

Primary: Change in Expression of Chemokine (C-X-C Motif) Ligand 9 (CXCL9), Chemokine (C-X-C Motif) Ligand 10 (CXCL10), and Interferon (IFN)-γ From Baseline to Week 12. — -3.10…

Primary: Post vs. Pre Change in Mid-frontal Theta Oscillations for iTBS vs. cTBS Stimulation — -0.043; 0.017 microVolts (uV) at FCz EEG electrode

Primary: Percent Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24 — -25.6; -30.4; -25.9; -6.3 percent — p=0.011

Primary: Number of Participants With Treatment-Emergent Adverse Events — 0; 3 Participants

Primary: Incidence Probability of Progression to Pulmonary Fibrosing-Interstitial Lung Disease (PF-ILDs) — 0.147; 0.249; 0.334; 0.395 Cumulative incidence probability

Primary: Change in Gene Expression Th2/IL-13, "T22"/IL-22, S100A7 and S100A8, Th1/IFN-gamma, and Th17/IL-17A Jointly Correlated — -0.28 z-score

Primary: Total Area Hair Count (Frontal) — 86.8 Count per cm^2

Primary: Rate of Decline in Forced Vital Capacity (FVC) Over the 24-week Double-blind Treatment Period — -17.9; 116.6; -90.3; 125.6 milliliter (mL) — p=0.6777

Primary: Annual Rate of Decline in Forced Vital Capacity - Overall Population — -80.82; -187.78 Milliliter per year — p=<.0001

Primary: The Proportion of Subjects Achieving at Least a 50% Reduction in Their Scalp Alopecia Areata Severity Scores (SALT Score) From Baseline Values — 8.7; 13.6 percentage of…